Dr. Blackwell is a distinguished leader in breast cancer research with a breadth of experience advancing multiple oncology programs through the clinic,” said Patrick Roberts, Pharm.D., Ph.D., Chief ...
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, ...
(MEMPHIS, Tenn. – November 6, 2025) The enzyme RNA polymerase II transcribes genes into messenger RNA. This process is guided by modifications to the enzyme’s “tail” called phosphorylation patterns.
The cell cycle is a fundamental process vital for organismal growth and stability. Its dysregulation underlies many human diseases, in particular cancers, making its monitoring essential in biological ...
[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...
Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial will determine ...
In this article, García-Vázquez et al. report valuable findings demonstrating that G2 and S phases expressed protein 1 (GTSE1), is a previously unappreciated non-pocket substrate of the cyclin ...
Recent advancements in cancer therapy focus on targeting critical mutations and regulatory pathways, particularly KRAS mutations and cyclin-dependent kinases (CDKs), which drive cancer progression.
This important chronobiological study in mice suggests that light modulated activity of Cdk5 activity on the PKA-CaMK-CREB signaling pathway provides missing molecular mechanistic details to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback